ProfileGDS5678 / 1415872_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 97% 97% 97% 97% 97% 97% 97% 98% 98% 97% 98% 98% 98% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.4747397
GSM967853U87-EV human glioblastoma xenograft - Control 29.2544697
GSM967854U87-EV human glioblastoma xenograft - Control 39.6786697
GSM967855U87-EV human glioblastoma xenograft - Control 49.7682597
GSM967856U87-EV human glioblastoma xenograft - Control 59.6364597
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.8825997
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.1803197
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.5263797
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.7743998
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.7503798
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.5720997
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.8817198
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.699298
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.7664998